Studies on antitumor and myelotoxic effect of Ledakrin and its selected analogues.
Ledakrin (Nitracrine) and its three analogues (C-846, C-857, C-1006) selected in primary in vitro and in vivo screening systems have been tested for antitumor activity in Lewis lung carcinoma, B16 melanoma of 16/C mammary adenocarcinoma bearing mice. Their effect on mouse bone marrow stem cells has also been evaluated by means of CFU-S technique. None of the tested compounds, including Ledakrin, revealed anti-tumor activity. Their bone marrow toxicity was minimal and comparable with that of Bleomycin.
D000609:Aminoacridines / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents; D001761:Bleomycin / Q000494:pharmacology; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000473:pathology; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009564:Nitracrine / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000633:toxicity
D000609:Aminoacridines; D000970:Antineoplastic Agents; D001761:Bleomycin; D009564:Nitracrine; D003520:Cyclophosphamide